HealthEquity, Inc. (NASDAQ: HQY) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 34.12 | EPS (ttm) | 2.77 | Insider Own | 3.14% | Shs Outstand | 83.60M | Perf Week | -0.04% |
| Market Cap | 7.90B | Forward P/E | 17.18 | EPS next Y | 5.50 | Insider Trans | -0.97% | Shs Float | 81.93M | Perf Month | -8.06% |
| Enterprise Value | 8.62B | PEG | 2.73 | EPS next Q | 1.16 | Inst Own | - | Short Float | 5.51% | Perf Quarter | 9.48% |
| Income | 237.00M | P/S | 5.80 | EPS this Y | 70.54% | Inst Trans | - | Short Ratio | 5.10 | Perf Half Y | 18.78% |
| Sales | 1.36B | P/B | 3.97 | EPS next Y | 16.43% | ROA | 7.23% | Short Interest | 4.52M | Perf YTD | 3.17% |
| Book/sh | 23.80 | P/C | 30.86 | EPS next 5Y | 12.49% | ROE | 11.43% | 52W High | 107.62 -12.18% | Perf Year | 3.24% |
| Cash/sh | 3.06 | P/FCF | 17.06 | EPS past 3/5Y | - 82.96% | ROIC | 8.55% | 52W Low | 72.76 29.89% | Perf 3Y | 33.87% |
| Dividend Est. | - | EV/EBITDA | 18.37 | Sales past 3/5Y | 15.06% 12.33% | Gross Margin | 75.21% | Volatility | 2.41% 2.85% | Perf 5Y | 43.26% |
| Dividend TTM | - | EV/Sales | 6.32 | EPS Y/Y TTM | 154.13% | Oper. Margin | 25.61% | ATR (14) | 2.99 | Perf 10Y | 173.47% |
| Dividend Ex-Date | - | Quick Ratio | 2.99 | Sales Y/Y TTM | 13.58% | Profit Margin | 17.36% | RSI (14) | 40.91 | Recom | 2.07 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.99 | EPS Q/Q | 27.84% | SMA20 | -3.63% | Beta | 0.23 | Target Price | 115.33 |
| Payout | 0.00% | Debt/Eq | 0.47 | Sales Q/Q | 7.67% | SMA50 | -5.09% | Rel Volume | 0.75 | Prev Close | 96.00 |
| Employees | 2,814 | LT Debt/Eq | 0.47 | Earnings | Dec 02 | SMA200 | 6.14% | Avg Volume | 849.04K | Price | 94.51 |
| IPO Date | Jul 31, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 3.92% 0.42% | Net Debt/EBITDA | 1.52 | Volume | 638,085 | Change | -1.55% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-31-26 | Reiterated | Deutsche Bank | Buy | $120 → $142 |
| Aug-28-26 | Reiterated | Telsey Advisory | $111 | |
| Jul-24-26 | Reiterated | BTIG | Buy | $115 |
| Jun-03-26 | Reiterated | RBC Capital | Outperform | $109 → $108 |
| Jun-01-26 | Reiterated | Wells Fargo | Overweight | $110 → $111 |
| May-29-26 | Reiterated | RBC Capital | Outperform | $109 → $108 |
| Apr-09-26 | Upgrade | BMO Capital | Market Perform → Outperform | $85 → $105 |
| Feb-24-26 | Reiterated | BMO Capital | $100 → $85 | |
| Feb-19-26 | Reiterated | Jefferies | Buy | $120 → $108 |
| Feb-18-26 | Reiterated | Barclays | Overweight | $118 → $110 |
Headquartered in Draper, Utah, and established in 2002, HealthEquity, Inc. furnishes technology-powered service platforms to both individual consumers and employers across the United States. The company provides cloud-based solutions designed to assist individuals in overseeing their healthcare expenditures and savings. These platforms enable users to make informed decisions about their health finances, pay medical bills, compare treatment options and costs, access personalized benefits and clinical data, earn incentives for wellness, and grow their savings through various investment avenues, including specific investment choices. In addition to these personal financial management tools, HealthEquity administers a range of health-related accounts, such as Health Savings Accounts (HSAs), Flexible Spending Accounts (FSAs), and Health Reimbursement Arrangements (HRAs). Its offerings also encompass a mutual fund investment platform, an automated online advisory service known as Advisor, COBRA continuation services, and the management of pre-tax commuter benefits programs. HealthEquity markets its services through a dedicated direct sales team, collaborates with benefits brokers and advisors, and leverages a comprehensive network comprising health plans, benefits administrators, consultants, and retirement plan record-keepers.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2026 1/31/2026 | FY 2025 1/31/2025 | FY 2024 1/31/2024 | FY 2023 1/31/2023 | FY 2022 1/31/2022 | FY 2021 1/31/2021 | FY 2020 1/31/2020 | FY 2019 1/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,363 | 1,313 | 1,200 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 337 | 400 | 507 | — | — | — | — | — | — | |
| Gross Profit | 1,024 | 913 | 693 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 342 | 328 | 223 | — | — | — | — | — | — | |
| Research and Development | 278 | 263 | 240 | — | — | — | — | — | — | |
| Other Operating Expense | 55 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | 349 | 322 | 230 | — | — | — | — | — | — | |
| Interest Expense | 53 | 57 | 61 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 13 | 12 | -53 | — | — | — | — | — | — | |
| Net Income Before Taxes | 309 | 277 | 116 | — | — | — | — | — | — | |
| Income Taxes | 72 | 62 | 19 | — | — | — | — | — | — | |
| Consolidated Net Income | 237 | 215 | 97 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 237 | 215 | 97 | — | — | — | — | — | — | |
| Net Income | 237 | 215 | 97 | — | — | — | — | — | — | |
| EPS (Recurring) | 2.80 | 2.50 | 1.11 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.80 | 2.50 | 1.11 | — | — | — | — | — | — | |
| EPS (Diluted) | 2.77 | 2.46 | 1.09 | — | — | — | — | — | — | |
| EBITDA | 469 | 489 | 338 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 34.12 | 34.83 | 101.30 | — | — | — | — | — | — | |
| Price To Sales Ratio | 5.76 | 5.61 | 8.01 | — | — | — | — | — | — | |
| Gross Margin | 75.13 | 69.54 | 57.75 | — | — | — | — | — | — | |
| Operating Margin | 25.61 | 24.52 | 19.17 | — | — | — | — | — | — | |
| Net Margin | 17.39 | 16.37 | 8.08 | — | — | — | — | — | — | |
| Shares Outstanding | 83 | 86 | 87 | — | — | — | — | — | — | |
| Market Capitalization | 7,844 | 7,368 | 9,607 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| DILLON ADRIAN T | Director | Aug 25 '26 | Option Exercise | 32.50 | 7,632 | 248,040 | 70,027 | Aug 27 |
| DILLON ADRIAN T | Director | Aug 25 '26 | Sale | 104.61 | 7,632 | 798,373 | 62,395 | Aug 27 |
| Fiore Michael Henry | EVP, CHIEF COMMERCIAL OFFICER | Jul 10 '26 | Sale | 95.00 | 2,354 | 223,630 | 52,244 | Jul 14 |
| Fiore Michael Henry | EVP, CHIEF COMMERCIAL OFFICER | Jul 02 '26 | Sale | 95.00 | 2,470 | 234,650 | 56,643 | Jul 07 |
| Fiore Michael Henry | EVP, CHIEF COMMERCIAL OFFICER | May 29 '26 | Sale | 95.00 | 3,142 | 298,490 | 59,113 | Jun 02 |
| Wellborn Gayle Furgurson | Director | May 28 '26 | Option Exercise | 47.21 | 2,439 | 115,145 | 22,172 | Jun 01 |
| Wellborn Gayle Furgurson | Director | May 28 '26 | Sale | 90.00 | 2,439 | 219,510 | 19,733 | Jun 01 |
| Ladd Delano | EVP, General Counsel | May 28 '26 | Sale | 90.00 | 7,500 | 675,000 | 91,141 | Jun 01 |
| Ladd Delano | EVP, General Counsel | Dec 19 '25 | Sale | 94.72 | 1,500 | 142,080 | 73,979 | Dec 23 |
| Rosner Elimelech | EVP, CHIEF TECHNOLOGY OFFICER | Dec 18 '25 | Sale | 95.45 | 10,959 | 1,046,090 | 45,742 | Dec 19 |
| Wellborn Gayle Furgurson | Director | Dec 12 '25 | Option Exercise | 50.41 | 4,339 | 218,729 | 24,072 | Dec 16 |
| Wellborn Gayle Furgurson | Director | Dec 12 '25 | Sale | 98.03 | 4,339 | 425,331 | 19,733 | Dec 16 |
| Ladd Delano | EVP, General Counsel | Nov 20 '25 | Sale | 104.56 | 1,500 | 156,840 | 75,479 | Nov 24 |
| Ladd Delano | EVP, General Counsel | Oct 20 '25 | Sale | 92.07 | 1,500 | 138,105 | 76,979 | Oct 22 |
| Fiore Michael Henry | EVP, CHIEF COMMERCIAL OFFICER | Oct 07 '25 | Sale | 88.21 | 1,781 | 157,102 | 49,795 | Oct 08 |